[Diltiazem compared with placebo in the prevention of myocardial ischemia during non-cardiac surgery].
The aim of this study was to assess the efficacy and safety of intravenous diltiazem to prevent myocardial ischemia during surgery on patients with ischemic heart disease undergoing non cardiac surgery under general anesthesia. Sixty patients scheduled for elective non cardiac surgery under general anesthesia were randomly assigned to two groups to receive diltiazem or placebo under double blind conditions. After an intravenous dose of 0.15 mg/kg of diltiazem or an equivalent amount of placebo, an infusion of 3 micrograms/kg/min of diltiazem or placebo was begun and continued until three hours after surgery. Thirty minutes after starting the infusion, anesthesia was induced by 0.1 mg/kg diazepam, 3 micrograms/kg of fentanyl and 0.3 mg/kg of etomidate. Intubation followed administration of 0.6 mg/kg of atracurium. Anesthesia was maintained with N2O/O2 and halothane and was the same for both groups. DII and V5 leads were monitored on a Cardiowiss CM-8 ECG machine that allowed us to set the alarm when ST segment variations reached 1 mm above or below baseline. We analyzed the number, intensity and duration of ischemic episodes recorded, as well as hemodynamic variables and side effects. Data for 46 patients were valid. At least one ischemic episode was experienced by 15% of patients in the placebo group and 1 in the diltiazem group (p < 0.05). The episodes were related to increased systolic arterial pressure (p = 0.04). ST segment decreases were 1.1 to 3.6 mm (1.75 +/- 0.7) (mean +/- SD) and lasted between 1 and 45 minutes (11.62 +/- 13.26) (mean +/- SD). No significant side effects were observed. Intravenous diltiazem administered to patients with ischemic heart disease under general anesthesia for non cardiac surgery was effective in our study for preventing intraoperative ischemic episodes.